Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia

Update Il y a 4 ans
Reference: NCT00126893

Woman and Man

Extract

This is a single center Phase 1 study to evaluate the safety, pharmacokinetics and pharmacodynamics of CC-401 in subjects with refractory acute myelogenous leukemia.


Inclusion criteria

  • Myeloid leukemia

Links